Advocacy intelligence hub — real-time data for patient organizations
Regeneron Pharmaceuticals — PHASE3
Amryt Pharma — PHASE3
Zhongnan Hospital
Ruijin Hospital
Regeneron Pharmaceuticals — PHASE3
Shanghai Jiao Tong University School of Medicine
Rahul Aggarwal — PHASE1, PHASE2
University of Kansas Medical Center
Children's Hospital of Fudan University — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
MYALEPT
Chiesi Farmaceutici S.p.A.
MYALEPT
(metreleptin)Orphan drugstandardChiesi Farmaceutici S.p.A.
Leptin Analog [EPC]
12.1 Mechanism of Action Adipocytes store lipids to meet the fuel requirements of non-adipose tissues during fasting. In patients with generalized lip...
Abhimanyu Garg, MD, MD
University of Texas Southwestern Medical Center
📍 DALLAS, TX
David Savage, Prof.
University of Cambridge Metabolic Research Laboratories
Lori Hartnett, MA, CCC-SLP/L
Amryt Pharmaceuticals DAC
📍 OMAHA, NE
Giovanni Ceccarini, Dr.
Endocrine Unit, University Hospital of Pisa
Marie-Christine Vantyghem, Prof.
Lille University
Julia von Schnurbein, Dr.
University of Ulm